Activating Sirtuin1 may be a host-directed strategy to fight tuberculosis infection, researchers from the Singapore Agency for Science, Technology and Research have reported. Read More
Progenics Pharmaceuticals Inc., of New York, said results of a phase II study of 1404, a PSMA-targeted small-molecule SPECT/CT imaging agent designed to visualize prostate cancer, published in the Journal of Nuclear Medicine, demonstrated the sensitivity of 1404 to detect prostate cancer using both visual and semiquantitative tumor to background (TBR) scores. Read More
Roche Holding AG, of Basel, Switzerland, said its member company Genentech disclosed that the FDA granted breakthrough therapy designation to Rituxan (rituximab) for pemphigus vulgaris, a rare, serious and life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes. Read More
Globeimmune Inc., of Louisville, Colo., said it entered a definitive purchase agreement for the sale of 12.8 million shares of its common stock to Nantcell Inc., of Culver City, Calif., a member of the Nantworks group. Read More
To push the envelope – increasing survival and decreasing toxicity – companies are harnessing new technology and mechanisms of action to develop the next generation of oncology drugs. Read More
Simon Pimstone, president and CEO of Xenon Pharmaceuticals Inc., said the company is dropping development of its moderate to severe facial acne candidate, XEN801, after the topical drug failed to separate from placebo in clearing lesions over the course of a 12-week phase II study. Read More
BARCELONA, Spain – French antibody developer Gamamabs SA is waiting on safety data for its first-in-class antibody targeting the type II anti-Müllerian hormone receptor (AMHR2) before including dose-expansion cohorts across three gynecological cancer indications. Read More
Inhibiting the enzyme glyoxalase 1 (Glo-1), which was originally identified as a metabolic housekeeping enzyme but also affects anxiety, relieved symptoms of depression more rapidly than Prozac (fluoxetine, Eli Lilly and Co.) in several different animal models. Read More
NEW DELHI – India's business environment will remain highly challenging for innovative pharmaceutical firms, according to BMI Research. The report comes on the heels of the February U.S. Chamber International IP Index, which ranks India very low in intellectual property (IP) – 43rd among 45 countries that represent 90 percent of the global GDP. Read More
